Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
- PMID: 11988246
- DOI: 10.1016/S0140-6736(02)08434-9
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Abstract
Background: Management of early-stage breast cancer in young women with mutations in BRCA1 or BRCA2 remains controversial. This study assessed the long-term risks of ipsilateral and contralateral breast cancer in a cohort of young women who underwent breast-conserving surgery followed by radiotherapy.
Methods: Between 1975 and 1998, 290 women with breast cancer diagnosed at age 42 years or younger underwent lumpectomy followed by radiotherapy at our hospital. We recruited 127 of these women for complete sequencing of BRCA1 and BRCA2. Demographic, clinical, pathological, and outcome data were recorded. The primary endpoints were rates of ipsilateral and contralateral breast cancer, in relation to germline BRCA1/2 status.
Findings: 105 women were classified as having sporadic disease (94 with wild-type or known polymorphisms and 11 with variants of unclear significance) and 22 as having genetic predisposition (deleterious mutations in BRCA1 [15] or BRCA2 [seven]). At 12 years of follow-up, the genetic group had significantly higher rates of ipsilateral (49% vs 21%, p=0.007) and contralateral events (42% vs 9%, p=0.001) than the sporadic group. The majority of events were classified as second primary tumours. No patient in the genetic group had undergone oophorectomy or was taking prophylactic agents such as tamoxifen.
Interpretation: Patients with germline mutations in BRCA1 or BRCA2 have a high risk of developing late ipsilateral and contralateral second primary tumours. With breast-conserving therapy, chemoprophylaxis or other interventions to reduce the rate of second cancers may be valuable. Alternatively, bilateral mastectomy may be considered, to minimise the risk of second tumours in the breasts.
Comment in
-
What options for treatment of hereditary breast cancer?Lancet. 2002 Apr 27;359(9316):1451-2. doi: 10.1016/S0140-6736(02)08465-9. Lancet. 2002. PMID: 11988240 No abstract available.
-
Management of early-onset breast cancer and BRCA1 or BRCA2 status.Lancet. 2002 Aug 24;360(9333):640; author reply 640-1. doi: 10.1016/S0140-6736(02)09787-8. Lancet. 2002. PMID: 12241952 No abstract available.
Similar articles
-
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.Eur J Cancer. 2005 Oct;41(15):2304-11. doi: 10.1016/j.ejca.2005.02.037. Epub 2005 Sep 1. Eur J Cancer. 2005. PMID: 16140006
-
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658. JAMA Oncol. 2015. PMID: 26181175
-
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.Cancer. 2003 Jan 1;97(1):1-11. doi: 10.1002/cncr.11048. Cancer. 2003. PMID: 12491499
-
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24. Breast Cancer Res Treat. 2010. PMID: 20033769 Review.
-
Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.Breast. 2013 Oct;22(5):561-8. doi: 10.1016/j.breast.2013.07.045. Epub 2013 Aug 21. Breast. 2013. PMID: 23972475 Review.
Cited by
-
Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.JAMA Netw Open. 2021 Apr 1;4(4):e216259. doi: 10.1001/jamanetworkopen.2021.6259. JAMA Netw Open. 2021. PMID: 33890992 Free PMC article.
-
Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.Breast Cancer Res Treat. 2023 May;199(1):25-33. doi: 10.1007/s10549-023-06904-4. Epub 2023 Mar 17. Breast Cancer Res Treat. 2023. PMID: 36930346
-
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.Breast Cancer Res. 2004;6(1):R8-R17. doi: 10.1186/bcr658. Epub 2003 Oct 24. Breast Cancer Res. 2004. PMID: 14680495 Free PMC article.
-
Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT).Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):385-91. doi: 10.1016/j.ijrobp.2010.02.005. Epub 2010 Jun 18. Int J Radiat Oncol Biol Phys. 2011. PMID: 20646866 Free PMC article.
-
Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer.Curr Breast Cancer Rep. 2020 Jun;12(2):66-74. doi: 10.1007/s12609-019-00350-2. Epub 2020 Feb 17. Curr Breast Cancer Rep. 2020. PMID: 33552388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous